9 research outputs found
Anatomic localization, localization extent, MNI coordinates, and Z scores for maximal gray matter volume differences between the local bias group and the global bias group of children.
<p>L: left; R: right.</p
Representative example of a global/local triad stimulus (left), mean global/local task scores (middle), and mean age (right) for the local bias group (yellow) and the global bias group (pink).
<p>*<i>p<0.05; ns</i> = non-significant.</p
3D rendering (left) and sagittal views (right) show the loss of gray matter volume between the local bias group and global bias group of children.
<p>L: left; R: right. For illustrative purposes, the maps were thresholded at <i>p</i> = 0.01.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.
<p>IgG4-RD RI, IgG4-related disease Responder Index.</p
Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.
<p>Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.
<p>Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.</p
Hazard ratio for risk of flare: Unadjusted Cox regressions.
<p>Hazard ratio for risk of flare: Unadjusted Cox regressions.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.
<p>IgG4-RD RI, IgG4-related disease Responder Index.</p
Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.
<p>Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.</p